Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Pseudopseudohypoparathyroidism (PPHP) is a rare imprinting disorder characterized by the Albright hereditary osteodystrophy (AHO) phenotype in the absence of parathyroid hormone resistance. PPHP results from heterozygous inactivating mutations in GNAS on the paternal allele, leading to haploinsufficiency of the stimulatory G-protein α-subunit (Gsα). The clinical hallmarks include brachydactyly, round face, obesity, subcutaneous ossifications and normal serum calcium and phosphate levels. Recognition of this imprinting mechanism is critical for accurate genetic counseling and risk assessment in affected kindreds.
Extensive genetic analyses across >200 probands from >30 unrelated families have identified over 100 distinct GNAS variants associated with PPHP, including missense substitutions, frameshift deletions, splice-site changes, and nonsense mutations. A recurrent 4-bp deletion in exon 7, c.2494_2497del (p.Asp832fs), has been reported in multiple kindreds and co-segregates with AHO features ([PMID:10487696]). Other hotspot mutations cluster at codons 189–190 ([PMID:9876352]) and in splice donor/acceptor sites ([PMID:11600516]). The variant spectrum underscores allelic heterogeneity and supports autosomal dominant paternal inheritance.
Segregation analyses document co-segregation of paternal GNAS mutations with PPHP in at least 19 additional affected relatives across multiple generations ([PMID:1505964]). Pedigree studies confirm absence of hormone resistance when GNAS defects are paternally inherited, consistent with tissue-specific imprinting. These data establish a high penetrance of AHO signs in carriers of paternal GNAS inactivating alleles.
Phenotypic evaluation reveals a consistent spectrum of AHO features: brachydactyly (HP:0001156), round facies (HP:0000311), obesity (HP:0001513), shortened metacarpals, subcutaneous calcifications and mild cognitive delay. Biochemical profiles remain normal for calcium, phosphorus, and PTH, distinguishing PPHP from pseudohypoparathyroidism type Ia where maternal inheritance causes endocrine resistance.
Functional studies demonstrate that GNAS inactivating mutations impair Gsα-mediated cAMP generation in vitro. Lymphoblast mRNA from patients with c.2494_2497del shows ~50% reduction in steady-state GNAS transcripts ([PMID:1505964]). Mouse models with heterozygous maternal versus paternal Gnas disruption recapitulate hormonal resistance only in maternal mutants, confirming imprinting and haploinsufficiency as the pathogenic mechanism. Rescue of Gsα expression restores cAMP responses in cell systems.
Integration of genetic and functional evidence supports a Definitive gene-disease relationship: numerous unrelated PPHP kindreds, multi-family segregation, and concordant functional assays. Genetic evidence reaches Strong (ClinGen Tier 3) with >100 pathogenic alleles and robust segregation. Experimental evidence is Strong (ClinGen Tier 3) given in vitro, animal, and rescue data. PPHP diagnosis should prompt targeted paternal GNAS testing, enabling precise risk stratification, family planning, and early recognition of AHO manifestations.
Key Take-home: Paternally inherited inactivating GNAS variants cause pseudopseudohypoparathyroidism by haploinsufficiency of Gsα, yielding an AHO phenotype without hormone resistance—mandating imprinting-aware genetic testing for accurate diagnosis and counseling.
Gene–Disease AssociationDefinitive
Genetic EvidenceStrong
Functional EvidenceStrongIn vitro cAMP assays, patient RNA studies, and mouse imprinting models confirm haploinsufficiency |